46 patents
Utility
Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
5 Dec 23
Methods of using glucokinase (GK) activators are generally disclosed herein, particularly in combination with insulin or insulin analogs.
Jennifer L. R. Freeman, Maria Carmen Valcarce Lopez
Filed: 18 Feb 21
Utility
Amorphous Form of Isoquinoline Derivative
30 Nov 23
The present invention provides an amorphous form of (S)-2-(3S,8S)-3-(4-(3,4-dichlorobenzyloxy)phenyl-7-((S)-1-phenylpropyl)-2,3,6,7,8,9-hexahydro-[1,4]-dioxino[2,3-g]isoquinolin-8-ylformylamino)-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)propionic acid dihydrochloride salt, pharmaceutical compositions comprising the same, methods of preparation and use thereof in treating conditions, such as diabetes, where modulation of the human GLP-1 receptor is beneficial.
Dharma Rao POLISETTI, Thomas Scott YOKUM, Yuanqiang SUN, James C. QUADA, Jr.
Filed: 17 Sep 21
Utility
Substitute Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof
5 Oct 23
Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating renal diseases are provided.
Adnan M.M. MJALLI, Dharma Rao POLISETTI, Jareer Nabeel KASSIS, Matthew J. KOSTURA, Mustafa GUZEL, Otis Clinton ATTUCKS, Robert Carl ANDREWS, Samuel VICTORY, Suparna GUPTA
Filed: 3 Apr 23
Utility
Crystalline Form of Hydrochloride Salt of Quinoline Derivative
5 Oct 23
The present disclosure relates to a crystalline form of trans-4-[1-(3-Chloro-phenyl)-7-methoxy-2,4-dioxo-3,4-dihydro-2H-pyrimido[5,4-c]quinolin-3-yl]-cyclohexanecarboxylic acid hydrochloride, methods of preparation, and its use as a therapeutic agent to treat inflammatory diseases.
Bapu GADDAM, Samuel VICTORY, Dharma Rao POLISETTI
Filed: 26 Jul 21
Utility
Salts or Co-crystals of {2-[3-CYCLOHEXYL-3-(TRANS-4-PROPOXY-CYCLOHEXYL)-UREIDO]-THIAZOL-5-YLSULFANYL}-ACETIC Acid and Uses Thereof
13 Jul 23
Sodium, piperazine, and hydrochloride salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]thiazol-5-ylsulfanyl}-acetic acid (“Compound 1”) are provided herein.
Jing TENG, Nathan E. GIGNAC
Filed: 7 Jun 21
Utility
Crystalline Forms of {2-[3-CYCLOHEXYL-3-(TRANS-4-PROPOXY-CYCLOHEXYL)-UREIDO]-THIAZOL-5-YLSULFANYL}-ACETIC Acid and Uses Thereof
13 Jul 23
The present disclosure relates to a) crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazo 1-5-ylsulfanyl}-acetic acid (“Compound I”); b) pharmaceutical compositions, comprising one or more crystalline forms of Compound I, and optionally, a pharmaceutically acceptable carrier; c) methods of treating a type of diabetes mellitus or other disorders by administering one or more crystalline forms of Compound I; and d) methods for the preparation of crystalline forms of Compound I.
Jing TENG, Yizheng CAO
Filed: 7 Jun 21
Utility
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
16 May 23
Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating renal diseases are provided.
Adnan M. M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
Filed: 11 Aug 21
Utility
Sulfoxide and Sulfone Glucokinase Activators and Methods of Use Thereof
6 Apr 23
Nhut DIEP, Philippe PITCHEN, Matthew RONSHEIM
Filed: 12 Feb 21
Utility
Substituted Fused Imidazole Derivatives and Methods of Treating Refractive Ocular Disorders
23 Mar 23
The present invention provides methods of treating refractive ocular conditions and related complications using compounds of Formula (I) and pharmaceutical compositions thereof either alone or in combination other active agents.
Otis Clinton ATTUCKS
Filed: 1 Feb 21
Utility
Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 yl}-phenoxy)-propyl]-diethyl-amine
13 Dec 22
The present invention relates to metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine.
William Kenneth Banner, Bapu Gaddam, Dharma Rao Polisetti, Robert Carl Andrews, Samuel Victory
Filed: 25 Mar 21
Utility
Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
23 Aug 22
Phenoxy acetic acids and phenyl propionic acids and their use in improving mitochondrial energy output in a subject are provided herein.
Per Sauerberg, Pavel Pihera, Zdenek Polivka, Miroslav Havranek, Ingrid Pettersson, John Patrick Mogensen
Filed: 9 Mar 21
Utility
Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
23 Aug 22
The present invention relates to crystalline forms of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethylamine (“COMPOUND I”) useful in the treatment of RAGE mediated diseases.
Zheqiong Wu
Filed: 14 Sep 20
Utility
Solid Compositions Comprising a Glucokinase Activator and Methods of Making and Using the Same
28 Jul 22
The invention relates to solid compositions comprising {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid, and methods of making and using such solid compositions.
Eric Benjamin, Thorsteinn Thorsteinsson, Siva Kumar Rapuru
Filed: 21 Sep 21
Utility
Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof
2 Jun 22
Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating renal diseases are provided.
Adnan M.M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
Filed: 11 Aug 21
Utility
Use of a Ppar-delta Agonist for Reducing Loss of Muscle Strength, Muscle Mass, or Type I Muscle Fibers In an Immobilized Limb
10 Mar 22
The present invention provides methods for reducing loss of muscle strength, muscle mass, or Type I muscle fibers in an immobilized limb by administering (E)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.
Maria Carmen VALCARCE LOPEZ, Eliot OHLSTEIN
Filed: 16 Jul 21
Utility
Methods of Treating Cognitive Impairment or Improving Cognitive Function
4 Nov 21
The present invention relates to methods of treating cognitive impairment or improving cognitive function in an individual having poor glycemic control, or having elevated level or one or more RAGE ligands, or having elevated level of one or more inflammatory biomarkers, or overexpressing RAGE, where the method comprises administering [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine (“COMPOUND I”) or a pharmaceutically acceptable salt thereof.
Maria Carmen Valcarce Lopez
Filed: 21 Apr 21
Utility
Substituted Fused Imidazole Derivatives and Methods of Treating Sickle Cell Disease and Related Complications
4 Nov 21
The present invention provides methods of treating sickle cell disease and related complications using compounds of Formula (I) and pharmaceutical compositions thereof either alone or in combination other active agents.
Otis Clinton Attucks
Filed: 13 Jul 21
Utility
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
28 Sep 21
Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating renal diseases are provided.
Adnan M. M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
Filed: 22 Sep 20
Utility
Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity
16 Sep 21
The present invention provides methods of inhibiting osteoclastogenesis or inhibiting osteoclast activity using fused imidazole derivative compounds and pharmaceutical compositions.
Otis Clinton ATTUCKS
Filed: 1 Jun 21
Utility
Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
24 Aug 21
The present invention provides methods for reducing loss of muscle strength, muscle mass, or Type I muscle fibers in an immobilized limb by administering (E)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.
Maria Carmen Valcarce Lopez, Eliot Ohlstein
Filed: 22 Oct 19